November 6 is the day that could make or break Biogen.
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Yumanity Therapeutics wants to be at the forefront of a neurodegenerative disease revolution, but is taking an unglamorous route to get there.